BUZZ-Arcturus falls as cystic fibrosis drug shows no improvement in initial analysis
Shares of Arcturus Therapeuticsfell 61.8% to $8.84 in premarket trading after an initial analysis of its experimental cystic fibrosis therapy showed no improvement in lung function at day 28. However, day 42 measurements indicated potential improvements. The company plans to start a 12-week safety and preliminary efficacy study in H1 2026. Prior to this news, the stock had risen 36.5% year-to-date.
Shares of Arcturus Therapeutics (ARCT.O) fall 61.8% to $8.84 premarket
Co says an initial analysis comparing lung function from day 1 and day 28 after treatment with its experimental cystic fibrosis therapy did not show improvement in a mid-stage study
However, measurements at day 42 suggests improvements in lung function
Encouraged by early signals of reduction in mucus plugging - ARCT
Experimental inhaled mRNA therapy ARCT-032 generally safe and well tolerated - co
Intend to initiate a 12-week safety and preliminary efficacy study in up to 20 CF participants in H1 2026
CF is an inherited genetic disorder that causes thick, sticky mucus to build up in the body’s organs, primarily affecting the lungs and pancreas
Up to last close, stock had risen 36.5% YTD
